No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 18 of the 40 quarters in the window, leaving 22 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 10.4x · 10Y median 25.6x · 36th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:57:50.704Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Pluri Inc. (PLUR) stock was $0.98 as of Oct 6, 2026, 1:51 PM EDT, down 5.14% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -77.3% · 3-year avg -37.8%/yr · 5-year avg -44.8%/yr
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders.
Biotechnology · Haifa, HA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.54
vs Estimate
$-0.66
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PLUR | $10.59M | $0.98 | -5.14% | -77.28% | -44.78% | -38.09% | N/A |
| 2TVRD | $10.59M | $1.13 | -0.94% | -97.12% | N/A | N/A | vs PLUR |
| 3LSTA | $10.56M | $1.16 | -7.94% | -49.83% | -40.75% | -32.84% | vs PLUR |
| 4LFWD | $10.52M | $6.53 | -2.10% | -28.40% | -43.18% | -53.24% | vs PLUR |
| 5GDTC | $10.51M | $0.89 | -12.03% | -49.59% | N/A | N/A | vs PLUR |
| 6MSLE | $10.37M | $8.05 | N/A | N/A | N/A | N/A | vs PLUR |
N/A
$335000.00
vs Estimate
$655000.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.98
High
N/A
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-1.90 | $-1.90 | $-1.90 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $10.19M | $10.19M | $10.19M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
